Common Contracts

EX-10.67 2 dex1067.htm DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT WITH LUPIN LTD. *Portions of this document marked [*] are requested to be treated confidentially. FINAL EXECUTION COPY DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT...

And License Agreement • May 5th, 2020 • New York

• Contract Type
  And License Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

This Development, Commercialization and License Agreement (this “Agreement”) is made and entered into effective as of September 30, 2009 (the “Effective Date”) by and between Lupin Ltd., a corporation organized under the laws of India and having its principal place of business at “B” Wing, Fifth Floor, Bandra Kurla Complex, Mumbai—400 051, India (“Lupin”), and Salix Pharmaceuticals, Inc., a corporation organized under the laws of the State of California in the United States of America and having its principal place of business at 1700 Perimeter Park Drive, Morrisville, North Carolina 27560-8404, U.S.A. (“Salix”). Lupin and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT between LUPIN LTD. and SALIX PHARMACEUTICALS, INC. Dated as of 31 March 2011

And License Agreement • May 10th, 2011 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York

• Contract Type
  And License Agreement
• Filed
  May 10th, 2011
• Company
  Salix Pharmaceuticals LTD
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This Amended and Restated Development, Commercialization and License Agreement (this “Agreement”) is made and entered into effective as of 31 March 2011 (the “Amendment Effective Date”) by and between Lupin Ltd., a corporation organized under the laws of India and having its principal place of business at “B” Wing, Fifth Floor, Bandra Kurla Complex, Mumbai – 400 051, India (“Lupin”), and Salix Pharmaceuticals, Inc., a corporation organized under the laws of the State of California in the United States of America and having its principal place of business at 1700 Perimeter Park Drive, Morrisville, North Carolina 27560-8404, U.S.A. (“Salix”). Lupin and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT Between LUPIN LTD. and SALIX PHARMACEUTICALS, INC. Dated as of September 30, 2009

And License Agreement • November 9th, 2009 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York

• Contract Type
  And License Agreement
• Filed
  November 9th, 2009
• Company
  Salix Pharmaceuticals LTD
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This Development, Commercialization and License Agreement (this “Agreement”) is made and entered into effective as of September 30, 2009 (the “Effective Date”) by and between Lupin Ltd., a corporation organized under the laws of India and having its principal place of business at “B” Wing, Fifth Floor, Bandra Kurla Complex, Mumbai—400 051, India (“Lupin”), and Salix Pharmaceuticals, Inc., a corporation organized under the laws of the State of California in the United States of America and having its principal place of business at 1700 Perimeter Park Drive, Morrisville, North Carolina 27560-8404, U.S.A. (“Salix”). Lupin and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”